203 related articles for article (PubMed ID: 10699994)
1. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer.
Kaserer K; Schmaus J; Bethge U; Migschitz B; Fasching S; Walch A; Herbst F; Teleky B; Wrba F
J Pathol; 2000 Mar; 190(4):450-6. PubMed ID: 10699994
[TBL] [Abstract][Full Text] [Related]
2. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
3. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
4. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
[TBL] [Abstract][Full Text] [Related]
5. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM
Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163
[TBL] [Abstract][Full Text] [Related]
6. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
7. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
8. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
10. Effect of mutation and conformation on the function of p53 in colorectal cancer.
Webley KM; Shorthouse AJ; Royds JA
J Pathol; 2000 Aug; 191(4):361-7. PubMed ID: 10918210
[TBL] [Abstract][Full Text] [Related]
11. [The expression of mutation p53 gene from circulating cancer cells of peripheral blood and the clinical significance in detecting the patients with colorectal cancer].
Ma GJ; Zhou JN; Shen ZL; Chen SQ; Zhu YQ; Wu XL; Xue KX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):186-8. PubMed ID: 16604493
[TBL] [Abstract][Full Text] [Related]
12. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
[TBL] [Abstract][Full Text] [Related]
13. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
14. Negative immunohistochemical staining of p53 protein does not always reflect wild-type p53 gene in cancer cells.
Horiuchi H; Kawamata H; Omotehara F; Fujii S; Fujimori T; Kuroda Y
J Gastroenterol; 2004 Aug; 39(8):801-3. PubMed ID: 15338377
[No Abstract] [Full Text] [Related]
15. Mutations of p53 gene in gastric carcinoma in Taiwan.
Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
[TBL] [Abstract][Full Text] [Related]
16. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
[TBL] [Abstract][Full Text] [Related]
17. P53 gene mutation spectrum and the relationship between gene mutation and protein levels in pterygium.
Tsai YY; Cheng YW; Lee H; Tsai FJ; Tseng SH; Chang KC
Mol Vis; 2005 Jan; 11():50-5. PubMed ID: 15682042
[TBL] [Abstract][Full Text] [Related]
18. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
19. Discordance of p53 mutations of synchronous colorectal carcinomas.
Eguchi K; Yao T; Konomoto T; Hayashi K; Fujishima M; Tsuneyoshi M
Mod Pathol; 2000 Feb; 13(2):131-9. PubMed ID: 10697269
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer.
Eguchi S; Kohara N; Komuta K; Kanematsu T
Cancer; 1996 Apr; 77(8 Suppl):1707-10. PubMed ID: 8608566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]